When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Common warts

Last reviewed: 22 Oct 2024
Last updated: 30 Oct 2024

Summary

Definition

History and exam

Key diagnostic factors

  • presence of risk factors
  • lesion growth over weeks to months
  • round, raised papule
  • tiny black dots on surface of lesion
Full details

Other diagnostic factors

  • satellite lesions
  • fingers or nail fold lesions
  • facial lesions
  • fissuring
  • hyperkeratosis
  • grayish-white or light brown color
  • filiform papule with sharp spikes
Full details

Risk factors

  • water immersion
  • occupations involving handling of meat or fish
  • nail biting
  • age under 35 years
  • immunocompromised
Full details

Diagnostic tests

1st tests to order

  • no initial test
Full details

Tests to consider

  • skin biopsy
  • immunoperoxidase stain
  • skin culture
Full details

Treatment algorithm

ACUTE

common wart: immunocompetent

common wart: immunocompromised

filiform wart

Contributors

Authors

Angela Yen Moore, MD

Director

Arlington Center of Dermatology

Primary Investigator

Arlington Research Center

Arlington

Clinical Assistant Professor

Baylor University Medical Center

Dallas

Clinical Assistant Professor

University of Texas Medical Branch

Galveston

TX

Disclosures

Dr. Moore receives funds as an advisory board member (A), consultant (C), clinical study investigator (I), and speaker (SP) – for Abbvie (I,SP), Almirall (C,I,SP), Arcutis (I), Biofrontera (C,I), Boehringer Ingelheim (I), Bristol-Myers Squibb (C,I), Dermavant (I), DS Biopharma (I), Eli Lilly (I), EpiHealth (A), Evolus (A), Galderma (I), Incyte (I), Janssen (I), Leo (A,SP), Mayne Pharma (C,I), Nimbus (I), Novartis (I), Parexel (I), Pfizer (I,SP), UCB (I), Verrica (I), Vyne (I,SP).

Acknowledgements

Dr Angela Yen Moore would like to gratefully acknowledge Dr Leonid Izikson, the previous contributor to this topic. LI declares that he has no competing interests.

Peer reviewers

Brenda L. Pellicane, MD

Dermatologist

Wayne State University School of Medicine

Department of Dermatology

Detroit

MI

Disclosures

BLP declares that she has no competing interests.

David Cassarino, MD, PhD

Assistant Professor

Department of Pathology and Laboratory Medicine

University of California

Los Angeles

CA

Disclosures

DC declares that he has no competing interests.

Jashin J. Wu, MD

Chief Dermatology Resident

University of California

Irvine

CA

Disclosures

JJW declares that he has no competing interests.

Sam Gibbs, FRCP

Consultant Dermatologist

Dermatology Department

The Great Western Hospital

Swindon

UK

Disclosures

SG declares that he has no competing interests.

  • Common warts images
  • Differentials

    • Flat warts
    • Palmoplantar warts
    • Seborrheic keratosis
    More Differentials
  • Guidelines

    • Guidelines for the prevention and treatment of opportunistic infections in children with and exposed to HIV
    • Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV​​
    More Guidelines
  • Patient information

    Warts

    HPV (human papillomavirus) vaccine

    More Patient information
  • padlock-lockedLog in or subscribe to access all of BMJ Best Practice

Use of this content is subject to our disclaimer